

**★ AAD 30: Basal Cell Carcinoma/ Squamous Cell Carcinoma: Documentation of Patient Input for Treatment Type – National Quality Strategy Domain: Person & Care-Giver Centered Experiences & Outcomes**

**DESCRIPTION:**

Patient involvement and proactivity in their treatment and care improves patient outcomes. Moreover, building a strong patient-doctor communicative relationship has been shown to increase patients' quality of life and satisfaction during treatment. When patients are not actively involved in the decision process, their priorities in the treatment process are not taken into consideration. National Comprehensive Cancer Network (NCCN) guidelines stipulate that based on patient preference, alternate therapies such as 5-fluorouracil, imiquimod, photodynamic therapy, or cryotherapy may be considered for superficial NMSCs. Physician appreciation of patients' expectations, priorities, and level of medical literacy is critical to assure an effective discussion of therapeutic options and provision of true informed consent. This provider-patient discussion to obtain informed consent does not require the presence of multiple treatment options, but it is an appropriate process for all decisions that carry significant risk, even when only a single option is available. Thus when a decision carries risk and uncertainty, informed consent and shared decision making are appropriate.

Given the variety of options available for Non-Melanoma Skin Cancer, NCCN Guidelines also recommend the customization of all treatment decisions to account for the particular factors present in the individual case and for patient's preference. The guidelines mention that while surgical approaches remain the most effective modality, other considerations such as function, cosmesis, and patient preference can lead to the choice of alternative modalities as the most optimal treatment method. Superficial basal cell carcinoma and squamous cell carcinoma in situ are low-risk tumors that can be effectively and efficiently treated with a variety of surgical and non-surgical modalities.

**INSTRUCTIONS:**

This measure is to be reported for all patients treated for at least one superficial basal cell carcinoma or squamous cell carcinoma in situ by scalpel-based excisional surgery (including standard excision and Mohs surgery) within the reporting period. Require documentation in the patient chart of a discussion carried out by the operating physician of the risks and benefits for at least one alternative treatment modality, including but not limited to the use of topical medications, destructive therapies (cryotherapy, electrodesiccation, curettage), and photodynamic therapy. A statement such as the following must be documented in the patient chart: "The patient (or legal caregiver) was informed of the risks and benefits, including known cure rates for alternative treatment modalities: [specify treatment], and provided with the opportunity to provide input into the treatment decision. Patient questions were answered." While this discussion should occur with every surgical encounter, reporting the discussion to meet the requirement for this measure is required only once a reporting period.

**Measure Reporting via Registry**

ICD-10-CM diagnosis codes, CPT codes or HCPCS codes and patient demographics are used to identify patients who are included in the measure's denominator. The listed numerator options are used to report the numerator of the measure.

The quality-data codes listed do not need to be submitted for registry-based submissions; however, these codes may be submitted for those registries that utilize claims data.

**DENOMINATOR:**

All patients treated for at least one superficial basal cell carcinoma or squamous cell carcinoma in situ by scalpel-based excisional surgery (including standard excision and Mohs surgery) within the reporting period.

**Diagnosis Codes for Identifying Patients with Basal Cell Carcinoma, Squamous Cell Carcinoma or Carcinoma In Situ of the skin:**

<b>ICD-10 Codes</b>	<b>Code Description</b>
C44.01	Basal cell carcinoma of skin of lip
C44.02	Squamous cell carcinoma of skin of lip
C44.111	Basal cell carcinoma of skin of unspecified eyelid, including canthus
C44.1121	Basal cell carcinoma of skin of right upper eyelid, including canthus
C44.1122	Basal cell carcinoma of skin of right lower eyelid, including canthus
C44.1191	Basal cell carcinoma of skin of left upper eyelid, including canthus
C44.1192	Basal cell carcinoma of skin of left lower eyelid, including canthus
C44.121	Squamous cell carcinoma of skin of unspecified eyelid, including canthus
C44.1221	Squamous cell carcinoma of skin of right upper eyelid, including canthus
C44.1222	Squamous cell carcinoma of skin of right lower eyelid, including canthus
C44.1291	Squamous cell carcinoma of skin of left upper eyelid, including canthus
C44.1292	Squamous cell carcinoma of skin of left lower eyelid, including canthus
C44.211	Basal cell carcinoma of skin of unspecified ear and external auricular canal
C44.212	Basal cell carcinoma of skin of right ear and external auricular canal
C44.219	Basal cell carcinoma of skin of left ear and external auricular canal
C44.221	Squamous cell carcinoma of skin of unspecified ear and external auricular canal
C44.222	Squamous cell carcinoma of skin of right ear and external auricular canal
C44.229	Squamous cell carcinoma of skin of left ear and external auricular canal
C44.310	Basal cell carcinoma of skin of unspecified parts of face
C44.311	Basal cell carcinoma of skin of nose
C44.319	Basal cell carcinoma of skin of other parts of face
C44.320	Squamous cell carcinoma of skin of unspecified parts of face
C44.321	Squamous cell carcinoma of skin of nose
C44.329	Squamous cell carcinoma of skin of other parts of face
C44.41	Basal cell carcinoma of skin of scalp and neck
C44.42	Squamous cell carcinoma of skin of scalp and neck
C44.510	Basal cell carcinoma of anal skin
C44.511	Basal cell carcinoma of skin of breast
C44.519	Basal cell carcinoma of skin of other part of trunk
C44.520	Squamous cell carcinoma of anal skin
C44.521	Squamous cell carcinoma of skin of breast
C44.529	Squamous cell carcinoma of skin of other part of trunk
C44.611	Basal cell carcinoma of skin of unspecified upper limb, including shoulder
C44.612	Basal cell carcinoma of skin of right upper limb, including shoulder
C44.619	Basal cell carcinoma of skin of left upper limb, including shoulder
C44.621	Squamous cell carcinoma of skin of unspecified upper limb, including shoulder
C44.622	Squamous cell carcinoma of skin of right upper limb, including shoulder
C44.629	Squamous cell carcinoma of skin of left upper limb, including shoulder
C44.711	Basal cell carcinoma of skin of unspecified lower limb, including hip
C44.712	Basal cell carcinoma of skin of right lower limb, including hip
C44.719	Basal cell carcinoma of skin of left lower limb, including hip
C44.721	Squamous cell carcinoma of skin of unspecified lower limb, including hip
C44.722	Squamous cell carcinoma of skin of right lower limb, including hip
C44.729	Squamous cell carcinoma of skin of left lower limb, including hip
C44.81	Basal cell carcinoma of overlapping sites of skin
C44.82	Squamous cell carcinoma of overlapping sites of skin
C44.91	Basal cell carcinoma of skin, unspecified

C44.92	Squamous cell carcinoma of skin, unspecified
D04.0	Carcinoma in situ of skin of lip
D04.10	Carcinoma in situ of skin of unspecified eyelid, including canthus
D04.111	Carcinoma in situ of skin of right upper eyelid, including canthus
D04.112	Carcinoma in situ of skin of right lower eyelid, including canthus
D04.121	Carcinoma in situ of skin of left upper eyelid, including canthus
D04.122	Carcinoma in situ of skin of left lower eyelid, including canthus
D04.20	Carcinoma in situ of skin of unspecified ear and external auricular canal
D04.21	Carcinoma in situ of skin of right ear and external auricular canal
D04.22	Carcinoma in situ of skin of left ear and external auricular canal
D04.30	Carcinoma in situ of skin of unspecified part of face
D04.39	Carcinoma in situ of skin of other parts of face
D04.4	Carcinoma in situ of skin of scalp and neck
D04.5	Carcinoma in situ of skin of trunk
D04.60	Carcinoma in situ of skin of unspecified upper limb, including shoulder
D04.61	Carcinoma in situ of skin of right upper limb, including shoulder
D04.62	Carcinoma in situ of skin of left upper limb, including shoulder
D04.70	Carcinoma in situ of skin of unspecified lower limb, including hip
D04.71	Carcinoma in situ of skin of right lower limb, including hip
D04.72	Carcinoma in situ of skin of left lower limb, including hip
D04.8	Carcinoma in situ of skin of other sites
D04.9	Carcinoma in situ of skin, unspecified

**CPT Codes for Identifying Excisions and Mohs Surgery:**

<b>CPT Codes</b>	<b>Code Description</b>
11600	Excision, malig lesion incl. margins, trunk, arms or legs, excised diameter 0.5 cm or less
11601	Excision, malig lesion incl. margins, trunk, arms or legs, excised diameter 0.6 to 1.0 cm
11602	Excision, malig lesion incl. margins, trunk, arms or legs, excised diameter 1.1 to 2.0 cm
11603	Excision, malig lesion incl. margins, trunk, arms or legs, excised diameter 2.1 to 3.0 cm
11604	Excision, malig lesion incl. margins, trunk, arms or legs, excised diameter 3.1 to 4.0 cm
11606	Excision, malig lesion incl. margins, trunk, arms or legs, excised diameter greater than 4.0 cm
11620	Excision, malig lesion incl. margins, scalp, neck, hands, feet, genitalia, excised diam 0.5 cm or less
11621	Excision, malig lesion incl. margins, scalp, neck, hands, feet, genitalia, excised diam 0.6 to 1.0 cm
11622	Excision, malig lesion incl. margins, scalp, neck, hands, feet, genitalia, excised diam 1.1 to 2.0 cm
11623	Excision, malig lesion incl. margins, scalp, neck, hands, feet, genitalia, excised diam 2.1 to 3.0 cm
11624	Excision, malig lesion incl. margins, scalp, neck, hands, feet, genitalia, excised diam 3.1 to 4.0 cm
11626	Excision, malig lesion incl. margins, face, ears, eyelids, nose, lips, excised diam greater 4.0 cm
11600	Excision, malig lesion incl. margins, trunk, arms or legs, excised diameter 0.5 cm or less
11601	Excision, malig lesion incl. margins, trunk, arms or legs, excised diameter 0.6 to 1.0 cm
11602	Excision, malig lesion incl. margins, trunk, arms or legs, excised diameter 1.1 to 2.0 cm
11603	Excision, malig lesion incl. margins, trunk, arms or legs, excised diameter 2.1 to 3.0 cm
11604	Excision, malig lesion incl. margins, trunk, arms or legs, excised diameter 3.1 to 4.0 cm
11606	Excision, malig lesion incl. margins, trunk, arms or legs, excised diameter greater than 4.0 cm
11620	Excision, malig lesion incl. margins, scalp, neck, hands, feet, genitalia, excised diam 0.5 cm or less
11621	Excision, malig lesion incl. margins, scalp, neck, hands, feet, genitalia, excised diam 0.6 to 1.0 cm
11622	Excision, malig lesion incl. margins, scalp, neck, hands, feet, genitalia, excised diam 1.1 to 2.0 cm
11623	Excision, malig lesion incl. margins, scalp, neck, hands, feet, genitalia, excised diam 2.1 to 3.0 cm

11624	Excision, malig lesion incl. margins, scalp, neck, hands, feet, genitalia, excised diam 3.1 to 4.0 cm
11626	Excision, malig lesion incl. margins, face, ears, eyelids, nose, lips, excised diam greater 4.0 cm
11640	Excision, malig lesion incl. margins, face, ears, eyelids, nose, lips, excised diam 0.5 cm or less
11641	Excision, malig lesion incl. margins, face, ears, eyelids, nose, lips, excised diam 0.6 to 1.0 cm
11642	Excision, malig lesion incl. margins, face, ears, eyelids, nose, lips, excised diam 1.1 to 2.0 cm
11643	Excision, malig lesion incl. margins, face, ears, eyelids, nose, lips, excised diam 2.1 to 3.0 cm
11644	Excision, malig lesion incl. margins, face, ears, eyelids, nose, lips, excised diam 3.1 to 4.0 cm
11646	Excision, malig lesion incl. margins, face, ears, eyelids, nose, lips, excised diam greater 4.0 cm
17313	Mohs micrographic technique, including removal of all gross tumor, surgical excision of tissue specimens, mapping, color coding of specimens, microscopic examination of specimens by the surgeon, and histopathologic preparation including routine stain(s) (eg, hematoxylin and eosin, toluidine blue), of the trunk, arms, or legs; first stage, up to 5 tissue blocks
17314	Mohs micrographic technique, including removal of all gross tumor, surgical excision of tissue specimens, mapping, color coding of specimens, microscopic examination of specimens by the surgeon, and histopathologic preparation including routine stain(s) (eg, hematoxylin and eosin, toluidine blue), of the trunk, arms, or legs; each additional stage after the first stage, up to 5 tissue blocks (List separately in addition to code for primary procedure)
17315	Mohs micrographic technique, including removal of all gross tumor, surgical excision of tissue specimens, mapping, color coding of specimens, microscopic examination of specimens by the surgeon, and histopathologic preparation including routine stain(s) (eg, hematoxylin and eosin, toluidine blue), each additional block after the first 5 tissue blocks, any stage (List separately in addition to code for primary procedure)

**NUMERATOR:**

Number of patients for whom there is documentation of patient (or legal caregiver) input regarding treatment options at least once per reporting period.

**Exclusions:**

None

**Potential Benchmarks:**

>80%. This benchmark will be adjusted based on the mean and standard deviation of the previous reporting years.

**RATIONALE:**

With over 2 million procedures performed for non-melanoma skin cancer (NMSC) in the United States Medicare population in 2006 and the number of surgical procedures expected to increase (at an annual rate of about 2.6% as noted from 2006-2008) it is important that the effectiveness of treatment options for different conditions and scenarios are discussed with the patient and documented. Documentation of patient input will encourage communication of treatment options between patients and providers, which can lead to improved outcomes in patients' quality of life and satisfaction during treatment.

**CLINICAL RECOMMENDATION STATEMENTS:**

This measure will assess the number of patient for which there is documentation showing patient (or legal caregiver) input in their treatment options. The goal of this measure is to encourage communication and it is postulated that one discussion is enough to enable the patient in all future discussions to make informed decisions and ask educated questions.

**COPYRIGHT:**

©American Academy of Dermatology/Association. All rights reserved.

The American Academy of Dermatology and the American Academy of Dermatology Association (collectively AAD/A) own all right, title, and interest in this quality measure. This quality measure is provided solely for the benefit of AAD/A and its members for the purposes specified herein and for other AAD/A purposes. It may not be used by other parties except with prior written approval of the AAD/A.